Clinical & Scientific

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.

Calidi Biotherapeutics' RedTail platform uses a virus to make tumors produce their own medicine, a strategy that could finally defeat solid cancers.

Beyond fixing connectivity on restrictive networks, Surfshark's update to its Dausos protocol reveals a larger ambition: setting a new, quantum-proof standard.

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

A new AI tool scores meals on insulin impact, not calories. Can this data-driven approach disrupt the wellness market where others have stalled?

An independent study reveals a Quebec-based platform dramatically improves patient outcomes and slashes clinical workload. Is this the new OS for healthcare?

A startup's audacious plan for a Moon hotel relies not on rockets, but on powerful digital simulations that de-risk humanity's next great leap.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

A new spray-dried plasma could end reliance on freezers, transforming trauma care from the battlefield to rural ERs. But can Velico navigate the path to market?

Asimov's AI-driven synthetic biology platform partners with McGill's Goodman Cancer Institute, aiming to break the manufacturing bottleneck for complex drugs.

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.

As Oncoinvent accelerates its Phase 2 trial, a novel alpha-emitter therapy shows promise against a deadly cancer, signaling progress in radiopharmaceuticals.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

A groundbreaking partnership turns millions of registered organ donors into potential living kidney donors, tackling a waitlist of 90,000 with one simple step.

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

Gelteq aims to replace needles with its ingestible gel, targeting diabetes and more. But can it balance this lofty goal with near-term revenue and tight finances?